Kornimate/medical-research-clean huggingface dataset:
using infrared spectroscopy to analyze volatile organic compounds (vocs) in the breath of patients with lung cancer

Conditions: Lung Cancer; Non Small Cell Lung Cancer

Summary: the goal of this clinical trial is to compare breath samples from patients with lung cancer, those with stable lung nodules, and individuals without lung cancer. the main questions it aims to answer are whether breath patterns are different in these groups and to see if breath patterns change after treatment in patients with lung cancer. participants will be asked to provide one breath sample, and two if they get treated. they will also be asked to fill out a questionnaire about their background and medical history.

globally, lung cancer accounts for the most cancer deaths in both sexes combined. it is believed to develop slowly through progressive accumulation of genetic mutations, hence the disease allows time for diagnosis and curative surgical treatment. five year survival rates for non-small-cell lung carcinoma (nsclc) can range from 57-61% when detected in the early stages of disease. this is compared with a survival rate of approximately 6% once distant metastases are present. however, disease diagnosis typically occurs when it has progressed to an advanced stage when patients present with signs and symptoms. therefore, technologies capable of asymptomatic disease detection will significantly impact lung cancer specific mortality. metabolomic profiling of cancer measures compounds produced as a result of cellular activity including volatile organic compounds (vocs) in exhaled breath. infrared spectroscopy is a proven technique for breath analysis that can measure chemical concentrations in the parts per trillion range for certain vocs. when coupled with machine learning techniques, this has the potential to be a novel approach for disease detection using exhaled breath.

Eligibility criteria:
inclusion criteria: study participants in the lung cancer and control cohorts must meet lung cancer screening criteria as defined by the plcom2012 and/or us preventative services task force (uspstf) risk criteria. exclusion criteria: * patients are not eligible if they are currently receiving treatment for lung cancer. * patients are not eligible for a second breath sample if it has been less than 6 months since last application of treatment. note: breath sampling technology is sensitive to chemicals produced by tobacco, cannabis and e-cigarettes as well as alcohol (consumed by the subject or used by the operator around the equipment). we ask participants to refrain from: * smoking (tobacco, cannabis or e-cigarettes) at least 4 hours before breath sampling; * consume alcohol (including mouthwash) at least 8 hours before breath sampling.
a comparison of bimatoprost sr to selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension

Conditions: Glaucoma; Open-Angle Ocular Hypertension

Summary: this study will evaluate the intraocular pressure (iop)-lowering effect and safety of bimatoprost sr compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not adequately managed with topical iop-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).


Eligibility criteria:
inclusion criteria: - diagnosis of either open-angle glaucoma or ocular hypertension in each eye that require iop lowering treatment. exclusion criteria: * eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months. * enrollment in other studies using bimatoprost sr.
expanded access to abbv-8e12

Conditions: Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)

Summary: this is an expanded access program (eap) for eligible participants. this program is designed to provide access to abbv-8e12 prior to approval by the local regulatory agency. availability will depend on territory eligibility. participating sites will be added as they apply for and are approved for the eap. a medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Eligibility criteria:

Keywords: expanded access, pre-approval access, compassionate use, special access program, named patient basis, special access scheme.
compass: a group act program for cancer patients treated at ucsf

Conditions: Cancer

Summary: cancer center psychosocial services (psycho-oncology) offers group psychoeducational and behavioral programs as part of its clinical service for cancer patients and services at the helen diller family comprehensive cancer center. clinical outcomes and acceptability/feasibility and implementation process data from these programs are routinely gathered in an effort to engage in continuous quality improvement for the department.

for this project, the study team is proposing to retrospectively analyze a de-identified data set of these data to report on pilot data on preliminary outcomes, acceptability and feasibility of the implementation of the compass: acting mindfully for a valued life, based upon acceptance and commitment therapy, an evidence-based behavioral intervention and facilitated by a licensed clinical psychologist in our department. this intervention was implemented as a series of clinical offerings for seven 7-session groups between september 2015 and october 2018 for 113 individual cancer patients and survivors. outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. participants completed surveys at 4 time points, pre and post, and two followup time points. measures of demographics, satisfaction and feasibility/acceptability were also collected. insights gathered from this study will be used to inform articles, grant applications and conference presentations on the implementation of behavioral interventions for cancer patients and survivors.

Eligibility criteria:
inclusion criteria: * english-speaking * treated for any kind of cancer at university of california, san francisco * sufficient cognitive ability to participate in group activities as determined by their attending medical oncologist or surgeon exclusion criteria: * non-english speaking * treated elsewhere for cancer * psychiatric illness that would affect the ability to participate in a group activity

Keywords: survivorship
social skills group training ("kontakt") for children and adolescent with high-functioning autism spectrum disorders

Conditions: Autism Spectrum Disorder (ASD); Attention Deficit Hyperactivity Disorder (ADHD); Anxiety; Depression

Summary: this trial investigates the behavioral effects of manualized social skills training (kontakt) in children´s and adolescents with high-functioning autism spectrum disorder with psychiatric comorbidity in a rct, multicenter study. n = 288 are recruited from 10 child and adolescent psychiatric clinics in stockholm county. the examination of genetic variants as predictors for outcome and a qualitative study of kontakt complete the trial.

there are few randomized controlled trials of social skills group training for the children's and adolescents with high functioning autism spectrum disorders (hfa)(1). the objective of this trial is to investigate the behavioral effects of the manualized social skills group training kontakt (2,3) and the role of genetic variants for training effects.

Eligibility criteria:
inclusion criteria: * children and adolescent with high-functioning autism (f84.5, f 84.9 according to international classification of diseases (icd-10). participants have been investigated with the autism diagnostic observation schedule (ados). * normal psychometric range of intelligence, intelligence quotient (iq)\> 70 according to wechsler intelligence scale for children- fourth edition (wisc-iv). * comorbid diagnosis: adhd (f90.0 and f98.8), anxiety syndrome (f41.1) and depression (f32.9) according to a best estimate clinical assessment. exclusion criteria: any behavioral disorder not currently allowing meaningful participation in group-based training for asd, e.g. presence of clinically diagnosed self-injury, conduct disorder (f91), hyperkinetic conduct disorder (f90.1), antisocial personality disorder (f60.2), borderline personality disorder (f60.3) or any form of schizophrenia or related psychotic disorder (f20-f29).

Keywords: autism spectrum disorder social skills training group training comorbidity intervention evidence-based
effect of probiotics on pre-diabetes and diabetes in china

Conditions: Type 2 Diabetes Mellitus

Summary: this study is aimed at verifying the effects of probiotics (kawai:dead s.thermophilus) on glucos management among t2dm and pre-diabetes chinese adult. additionally, the investigators intend to verify the effects of probiotics on modifying the structure and function of gut microbiome.

methods: double-blind, randomized controlled trial. number of participants: 160 patients with pre-diabetes and 60 diabetes. intervention time: 3months. data and specimen collection time: at baseline and after the intervention. observation index 1. physical measurement: gender, age, weight, bmi, waist circumference, hip circumference, waist-to-hip ratio, systolic pressure, diastolic blood pressure. 2. lifestyle questionnaire: diet, drinking, exercise, sleep and other habits. 3. blood test: blood glucose, ogtt, blood lipid, tnf-a, il-6, il-10, lps, glp-1, gut microbiome metabolism products, t2dm related methylation. 4. gut microbiome detection: gut microbiome 16sr dna sequencing, gut microbiome bioinformatics analysis

Eligibility criteria:
inclusion criteria: 1. meet diabetes/pre-diabetes diagnostic criteria 2. bmi 18-35kg/m2 exclusion criteria: 1. patients with diabetes or hyperlipidemia, and need regular use of drugs. 2. secondary obesity or diabetes 3. digestive, tumor, heart, lung, kidney, rheumatic immunity and other systemic serious diseases 4. pregnant women, women ready for pregnancy, and nursing mothers 5. take antibiotics or bacterial agents within 1 month 6. diarrhea or abscess in 1 month or blood or other abnormal feces 7. diabetics have a history of more than 2 years 8. the ogtt experiment of diabetic patients fg≥9mmol/l or 2h≥14mmol/l

Keywords: pre-diabetes,diabetes,probiotics
first-line therapy of stage iv colorectal cancer

Conditions: Stage IV Colorectal Cancer

Summary: assessment of safety and toxicity, definition of the dose limiting toxicity (dlt) of the combination therapy consisting of capecitabine, oxaliplatin, bevacizumab and imatinib.

the monoclonal anti-vegf antibody bevacizumab has been approved for the treatment of stage iv colorectal cancer. the tyrosine kinase inhibitor imatinib mesylate has been shown to efficiently target pdgf-signalling. blocking pdgfr-signalling leads to disruption of pericytes from the endothelium and reverses the maturation status thereby enhancing the sensitivity to anti-vegf therapy.this background forms a rationale for a combined therapeutic pdgf and vegf inhibition. since bevacizumab shows best activity when used in combination with chemotherapy, capecitabine and oxaliplatin are included in this protocol. patients with stage iv colorectal cancer and no prior chemotherapy can enter the study. patients receive oral imatinib once a day on days 1-21. oral capecitabine is given on days 1-14 bid, oxaliplatin and bevacizumab are given on day 1. courses are repeated every 22 days in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * histologically proven inoperable colorectal cancer * adult patients \>= 18 years of age * ecog \<2 exclusion criteria: * preceding chemo- or immunotherapy with the exception of adjuvant or neoadjuvant treatment of non-metastatic disease ending ≥ 6 month prior to study inclusion. progression within 6 month after the end of adjuvant therapy must be excluded. * other malignancies with the exception of basal cell carcinoma or successfully treated carcinoma in situ of the cervix uteri. * no history of severe comorbidities, i. e. uncontrolled hypertension, gi-bleeding, congestive heart-failure nyha class ii-iv, symptomatic coronary heart disease, myocardial infarction within 1 year prior to study inclusion, serious cardiac arrhythmias requiring medication, grade ii or greater peripheral vascular disease and other severe uncontrolled co-morbidities * no history of stroke or other cns-diseases (tumors, seizure, transient ischemic attack etc.) * ≥ grade ii peripheral artery vascular occlusive disease * preexisting neuropathy ≥ grade 1 * interstitial pneumonia or lung fibrosis * serious, nonhealing wound, ulcer, or bone fracture * preceding irradiation an indicator lesion except for documented progressive disease during irradiation and termination of irradiation ≥ 4 weeks from study inclusion * thromboembolic or bleeding events within the last 6 month * need for therapeutic anticoagulation (heparin, cumarin) * use of ass \> 325 mg/die or nsar * proteinuria \> 1+ (stix) as long as urine protein \>1g/24h

Keywords: aio colorectal cancer 0205 capecitabine oxaliplatin bevacizumab imatinib
immediate effects of myofascial release techniques on balance in young adults with pes planus

Conditions: Flat Foot

Summary: the plantar fascia is a thick, multi-layered, non-elastic fibrous tissue band that extends along the plantar surface of the foot.the configuration of the plantar fascia is generally considered as a dense, longitudinally arranged fiber band divided into medial, central, and lateral components. the most significant functional role of the plantar fascia is to maintain the arch structure of the foot, providing a stable support base while standing and absorbing dynamic reaction forces during walking.pes planus is a rather general term with many definitions. staheli described pes planus as a "foot with a broad base of support," commonly known as flatfoot in layman's terms. in a study involving 80 female participants aged 65 and older, 90% of foot deformities observed while standing were identified as pes planus. generally, pes planus is a condition characterized by excessive pronation of the rear part of the foot and a lowering of the medial longitudinal arch. during the push-off phase of walking, the pronation moment generated by the ground reaction force flattens the arch as the subtalar joint rotation combines. the shift in position in the talus bone causes the navicular bone to drop. the plantar calcaneonavicular ligament tightens, and the tibialis posterior muscle lengthens. abnormalities in the bones of the foot, dysfunction of the tibialis posterior muscle, achilles tendon shortening, or muscle weakness can contribute to pes planus. individuals with pes planus may experience foot and leg pain with exercise, physical activity, and prolonged walking, which can limit their level of physical activity. research has examined the relationship between pes planus and various physical parameters, and it has been found that one of these parameters, balance, is negatively affected by the presence of pes planus.

participant information, including age, gender, height, body weight, and body mass index, was recorded using a general form. dynamic and static balance was assessed before and after the interventions in the study groups. three specialist physiotherapists conducted measurements and evaluations (navicular drop, static and dynamic balance). the assessing physiotherapist remained consistent throughout, and they were unaware of the participant groups. an expert in manual therapy administered the mrts. statistical analysis was performed by a separate researcher uninvolved in the practical aspects of the study.

Eligibility criteria:
inclusion criteria: * volunteering for study participation, * being between the ages of 18-25 * presence of pes planus. exclusion criteria: * presence of orthopedic conditions other than pes planus, * having a history of lower extremity surgery * presence of neurological or rheumatological disorders, * having a problem with vision or hearing * participating in regular physical activity (\>150 min/week)

Keywords: pes planus myofascial release postural balance randomized controlled trial
health promotion intervention in mental health care

Conditions: Unhealthy Lifestyle of Persons With Mental Disorders

Summary: overweight and obesity have become a serious global public health problem and the prevalence of these conditions is even higher among persons with mental disorders, compared with the general population. overweight and obesity are partially associated with sedentary lifestyles and unhealthy eating habits. the aim of the study is to examine the effectiveness and cost-effectiveness of a health promotion intervention targeting physical activity and eating habits in persons with mental disorders. the study hypothesis is that between baseline and the end of the intervention, and after a 6-month follow up period, significant differences in the primary and secondary outcomes between the intervention and control group will be identified. the investigators also hypothesize that the health promotion intervention will be cost-effective.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * living in sheltered housing * diagnosed according to the diagnostic and statistical manual of mental disorders (dsm-iv manual)

Keywords: lifestyle mental disorder
investigating modified protocols of oral immunotherapy to validate efficacy and safety

Conditions: Peanut Allergy; Milk Allergy, Cow's; Egg Allergy

Summary: protocols for oral immunotherapy (oit) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in european and canadian official guidelines. there has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. this study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.


Eligibility criteria:
inclusion criteria: * a history suggestive of immediate allergy to the food. a convincing clinical history of an ige mediated reaction to a specific food will be defined as a minimum of 2 mild signs/symptoms or 1 moderate or 1 severe sign/symptom that was likely ige mediated and occurred within 120 minutes after ingestion or contact * the presence of at least one of the following confirmatory tests: * positive spt to the culprit food allergen (weal diameter 3 mm larger than that of the normal saline control). the allergens used will be commercial extracts of the foods (omega labs, toronto, ontario). * detection of serum specific ige (\>0.35 ku/l) to the culprit food or any of its proteins, measured by fluorescence enzyme immunoassay (phadia, cap system, uppsala, sweden). exclusion criteria: * patients who have uncontrolled respiratory disease (asthma, cystic fibrosis, etc.) * patients who present with intercurrent disease active at the time of starting desensitization. * non ige mediated or non-immunological adverse reactions to milk or peanuts. * malignant or immunopathological diseases and/or severe primary or secondary immune deficiencies. * patients receiving oral immunosuppressor therapy. * patients receiving β-blockers (including topical formulations), or who receive daily doses of nsaids, aspirin or ace inhibitors for cardiac issues. * associated diseases contraindicating the use of epinephrine: cardiovascular disease, severe hypertension or hypotension. * patients diagnosed with eosinophilic gastrointestinal disorders, including patients with a history of antacid use for reflux related to food impaction or with a history of esophageal spasm. * patients already tolerating processed/cooked forms of the food (e.g.,baked goods with milk).
mobile phone-administered triage tool to followup on discharged trauma patients

Conditions: Wounds and Injury

Summary: after being admitted to and then discharged from a hospital in cameroon for having experienced an injury, there is no established way for the health system to check in on how the discharged person is doing. the investigators have developed a set of questions with the hope that asking these questions--over the phone--to those who have been discharged from the hospital will allow them to determine which post-discharge patients would benefit from further care. the investigators believe that asking these questions over the phone is a good way of determining which post-discharge trauma patients would benefit from further care.

broadly, this study aims to answer three questions. (1) is it feasible to call discharged trauma patients on their mobile phones to check up on them? (2) can a defined set of questions help determine which discharged trauma patients require further medical care (and which discharged trauma patients do not require further medical care)? (3) will checking in on discharged trauma patients reduce their experience of disability and economic consequences? if an individual was a trauma patient who was admitted at and then discharged from one of the study's partner hospitals in cameroon, the discharged individual (hereafter referred to as "the participant') will be receiving phone calls from one of the study's research assistants at the following post-discharge timepoints: 2 weeks, 1 month, 3 months, and 6 months. whether the research assistant administers the defined set of questions developed by the study's investigators (see question 2, above) will depend on when the participant was discharged from the hospital. regardless, all participants will be asked other important questions about the injury and any associated disabilities and economic consequences.

Eligibility criteria:
inclusion criteria: * all trauma registry patients at participating hospitals who provided cellphone numbers and are alive at hospital discharge are eligible for inclusion regardless of age, injury severity, or hospital disposition status.

Keywords: aftercare telemedicine africa south of the sahara
effect of temperament, anxiety and depression on immuninity in colorectal cancer patients. effetti del temperamento, dell'ansia e della depressione sulla sopravvivenza globale e sulla risposta immunitaria del paziente affetto da adenocarcinoma colo-rettale.

Conditions: Temperament; Anxiety; Depression; Colorectal Cancer

Summary: aim of the study is to evaluate if temperament, anxiety and depression can affect immunity and influence survival in colorectal cancer patients

120 prospective patients, with non-metastatic colorectal cancer, will be evaluated with questionnaires and auto-questionnaires in order to assess temperament, anxiety and depression. the immunity status will be assessed by a blood sample with the aim to evaluate cell-mediated immunity. survivall will be related to level of anxiety/temperament/depression and cell-mediated immunity. univariate and multivariate model analisys will be performed in order to evaluate if anxiety/temperament/depression and cell-mediated immunity can be considered as prognostic factors.

Eligibility criteria:
inclusion criteria: diagnosis of non-metastatic colorectal cancer exclusion criteria: previous other primary malignancies immunodepression diagnosis of major deppression diagnosis of anxiety/depression syndrome

Keywords: temperament anxiety depression colorectal cancer